<DOC>
	<DOCNO>NCT00607438</DOCNO>
	<brief_summary>This Phase II , open-label , non-randomized study patient locally advance metastatic breast cancer . Each cycle 4 week length . Patients receive Abraxane weekly 3 week . Patients receive Abraxane week 4 ( rest week ) . Nexavar give continuously . Patients radiologically evaluate every 8 week response . Patients continue receive study treatment disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Phase II Study Of Abraxane Nexavar First-Line Treatment Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Patients must sign IRBapproved informed consent . 2 . Patients must histologically confirm locally advanced metastatic breast cancer . 3 . Patients must HER2negative . 4 . Patients must measurable disease , define RECIST criterion . 5 . Patients may receive prior adjuvant chemotherapy breast cancer , include taxanecontaining regimen , provide treatment complete least 12 month prior enrollment . 6 . Patients must &lt; 18 year age . 7 . Patients must ECOG Performance Status 0 1 . 8 . Patients ' estimate life expectancy must least 12 week . 9 . Patients must adequate liver function define : total bilirubin within normal limit aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 X upper limit normal ( ULN ) ( &lt; 5 X ULN patient liver involvement ) . 10 . Patients must alkaline phosphatase ≤ 2.5 X ULN . Alkaline phosphatase may &gt; 2.5 x ULN bone metastasis present absence liver metastasis , patient 's bilirubin ≤ ULN . 11 . Patients must adequate renal function define : creatinine ≤ 1.5 mg/dL . 12 . Patients must adequate bone marrow function , include absolute neutrophil count ( ANC ) &gt; 1500/µL , platelet count &gt; 100,000/µL , hemoglobin &gt; 9 g/dL . 13 . Patients must normal baseline leave ventricular ejection fraction ( LVEF ) . 14 . Patients must normotensive . Patients take antihypertensive medication must blood pressure control great 140/90 . 15. International Normalized Ratio ( INR ) &lt; 1.5 prothrombin time ( PT ) /partial thromboplastin time ( PTT ) within normal limit . 16 . Patients must either child bear potential negative serum pregnancy test within 7 day prior registration . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal least 12 month . 17 . Patients childbearing potential must agree use effective contraceptive measure study treatment reasonable time thereafter . 18 . Patients must willing able comply schedule visit , treatment plan laboratory testing , accessible followup . 1 . Patients receive prior chemotherapy treatment locally advance metastatic breast cancer . 2 . Patients receive prior Abraxane Nexavar . 3 . Patients history hypersensitivity suspect allergy taxanes , component taxanes , Abraxane , Nexavar . 4 . Patients serious intercurrent medical psychiatric illness , include serious active infection . 5 . Patients untreated active brain metastasis . Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis . 6 . Patients history thrombosis . 7 . Patients thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 8 . Patients symptomatic congestive heart failure baseline echocardiogram LVEF &lt; ULN . 9 . Patients congestive heart failure &gt; class II New York Heart Association ( NYHA ) . Patients must unstable angina ( anginal symptom rest ) , new onset angina ( begin within last 3 month ) , myocardial infarction within past 6 month . 10 . Patients cardiac ventricular arrhythmia require antiarrhythmic therapy . 11 . Patients history , active , bowel perforation inflammatory bowel disease . 12 . Patients active peptic ulcer disease symptom suggest possible ulcer ( discontinuation chronic NSAID therapy advise , possible , use protonpump inhibitor recommend . ) 13 . Patients plan receive concurrent therapy treat locally advance metastatic breast cancer study treatment period . 14 . Any patient pregnant lactating . 15 . Patients proteinuria &gt; +1 baseline dipstick , +2 , 24hour urine total protein &gt; 250 mg. 16 . Patients undergone major surgery , open biopsy , significant traumatic injury within 28 day , minor surgery within 14 day . ( The placement Mediport vascular access device permit perform least 7 day prior registration ) . 17 . Patients &gt; Grade 2 peripheral neuropathy ( NCICTC v3.0 ) painful neuropathy . 18 . Patients experience type bone fracture within 12 month undergone joint replacement surgery within 6 month . 19 . Patients serious nonhealing wound . 20 . Patients know human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. 21 . Patients require anticoagulant ( exception lowdose Coumadin , ASA , Plavix Heparin maintenance vascular access patency ) . 22 . Patients evidence history bleed diathesis coagulopathy . 23 . Patients experience hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first dose study drug . 24 . Patients pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug . 25 . Patients condition impair patient 's ability swallow whole pill patient malabsorption problem . 26 . Patients use St. John 's Wort rifampin ( rifampicin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Locally Advanced Metastatic</keyword>
</DOC>